Library Guides: Tulane University LaSOR Project ECHO (Extension For Community Healthcare Outcomes): ECHO: Presentations of Session Topics

Educational opportunities + Forms + Organizations of interest + Contacts

ASAM (American Society of Addition Medicine)
Updated.Resource areas
Drug Disposal: Drug Take Back Locations (FDA)

Millie Mattered Advocacy Drug Epidemic Walks -Outreach & Awareness in Louisiana Facebook page Millie Mattered for more information on my advocacy. You can contact me on Facebook messenger, or email me milliemattered@gmail.com Phone (318)403-2414

More information: Facebook page Millie Mattered OR milliemattered@gmail.com

Every Step Matters!

Share a Case
Presentation Form - No identifiers for patient, place, ...

Tulane - Center for Continuing Education
Contact for CME Credit

LaSOR Project ECHO Sessions are in order of date of presentation, most recent to oldest session

PDF versions of the PowerPoint presentations follow. References and related resources may also be available here.

LaSOR Project ECHO Series 4: April 2024-

DoxyPEP: the Revolutionary New STI Prevention Tool (April 18, 2024)
Brandon Mizroch, MD/MBBS, Utah AETC Project Manager
Interface Between Chronic pain & Opioid Use Disorder ( April 11, 2024)
Presenter: Mohammed Issa, MD
Medical Director/Pain Fellowship Program Director
Brigham and Women’s Hospital
Assistant Professor/ Harvard Medical School
Methamphetamines (April 4, 2024)
Lee Michals MD, Tulane Addiction Medicine

LaSOR Project ECHO Series 4: February 2024 - March 2024

Adolescent and Transitional Age Substance Use (March 28, 2024)
Faculty/Presenter: Lee Michals, MD
Federal changes to OTPs: Summary of changes in Louisiana (March 21, 2024)
Presenter: Ellen Dancel, PharmD, MPH and Traci Perry, MSN, RN.
Faculty: Lee Michals, MD
Methodone fact sheet
Methadone/Opioid Treatment Regulatory Updates (3-21-2024)

Medications for the Treatment of Opioid Use Disorder (Federal Register) - https://www.govinfo.gov/content/pkg/FR-2024-02-02/pdf/2024-01693.pdf

"Expanding buprenorphine prescribing: Community and clinician interventions" (March 14, 2024)

"Post Hospitalization Transition of Care Models for SUD" presented by Dr. Lee Michals. (March 7, 2024)

Use of Toxicology Testing in MOUD and Pain Management (February 22, 2024)
Presenter: Elisabeth Fowlie Mock, MD, MPH, FAAFP
LaSOR Project ECHO

recording 2-22-2-24
passcode is required

Supply and Access Issues with Buprenorphine (2-15-2024)
Faculty/Presenter: Michael Palladini, RPh MBA
---
Faculty: Lee Michels, MD, Tulane School of Medicine
Psychiatry Chair: John Thompson, MD
Addiction Fellowship, Director: Ken Roy, MD
Faculty/Program Facilitator: Claudia Achoja, MSN, FNP-C
Program Administrator: Kevin Massey, MS
Saving Lives: How would you do it? (February 8, 2024)
Presenter: George Singletary MD MPH
Opioids and CVD (February 1, 2024)
Presenter: George Singletary MD MPH

Series 4: January 2024 Happy New Year! Year 4 of the Tulane ECHO Addiction.-

Stimulant Use Disorder and treatment in Women (Pregnancy) -- (January 25, 2024)
Presenter: Safia Mohiuddin MD MPH
Adolescent Treatment Facilities (January 18, 2024)
Presenter: George Singletary MD MPH
GLP1 Receptor Agonists. Recent Publications (January 11, 2024)
Presenter: George Singletary MD MPH

FDA: 01-11-2024 FDA Drug Safety Communication -Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity Preliminary evaluation does not suggest a
Content current as of:
01/11/2024 - Preliminary evaluation does not suggest a causal link
PubMed search: ((glp1r agonists) OR (semaglutide)) AND (suicide)

Modernizing Opioid Treatment Act (January 4, 2024)
Presenter: George Singletary MD MPH

Series 3,: December 2023-

Nalmefene and Seasons Greetings (December 28, 2023)
Presenter: George Singletary MD MPH

Stolbach AI, Mazer-Amirshahi ME, Nelson LS, Cole JB. American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time. Clin Toxicol
Erratum in: Clin Toxicol (Phila). 2023 Nov;61(11):1012. PMID: 38039052.

Buprenorphine and fatality risk during Fentanyl exposure...new article discussion -(December 21, 2023)
Presenter: George Singletary MD MPH

Dai, Z., et. al. (2023). Quantifying a potential protective effect of buprenorphine on fatality risk during acute fentanyl exposures. Journal of substance use and addiction treatment, 158, 209252. Advance online publication.
___________________

NMPOU (Non-medical prescription opioid use) and Adolescents (December 14, 2023)
Presenter: George Singletary MD MPH

Byregowda, H., Alinsky, R., Wang, X., & Johnson, R. M. (2023). Non-medical prescription opioid use among high school students in 38 U.S. States. Addictive behaviors reports, 17, 100498. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234833/

Global Opioid Use and Dependence (December 7, 2023)
Presenter: George Singletary MD MPH

Discussion: The Modernizing Opioid Treatment Access Act (SUPPORT H.R. 1359 AND S.644)

Series 3: November, 2023-

Long-Acting Buprenorphine in the Field (November 30, 2023)
Presenter: George Singletary MD MPH
Screens and Evals (Evidence based screening) (November 16, 2023)
Faculty/Presenter: George Singletary MD MP

NIDA-Screening and Assessment Tools Chart
OBOT Stability Index
From Denied to Dispensed: ACTIVATING COMMUNITY PHARMACISTS TO IMPROVE ACCESS TO MOUD (November 9, 2023)
Guest Presenter: Tyler J. Varisco, PharmD, PhD
University of Houston College of Pharmacy
more...less...
CONTACT: TJVARISC@CENTRAL.UH.EDU
citation: Robinson JC. Managed consumerism in health care. Health Aff (Millwood). 2005 Nov-Dec;24(6):1478-89. doi: 10.1377/hlthaff.24.6.1478. PMID: 16284020.

Common Brain Pathways in Addiction (November 2, 2023)
Common Brain Pathways in Addiction (November 2, 2023)
Presenter: George Singletary MD MPH

Series 3: October 2023-

Predictors Opioid Relapse (October 26, 2023)
Presenter: George Singletary MD MPH
Community Drug Checking (October 19, 2023)
Presenter: George Singletary MD MPH

Discussion (10-19-23) -- FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders (October 10, 2023)
Discussion(10-19-2023) -Virginia plans to test sewage water to track fentanyl abuse Wastewater fentanyl tracking can be so precise that it can tell if one neighborhood of around 3,000 people is experiencing a surge in fentanyl use.
... Wastewater fentanyl tracking can be so precise that it can tell if one neighborhood of around 3,000 people is experiencing a surge in fentanyl use.
Discussion (10-19-23) - The Americans with Disabilities Act and the Opioid Crisis: Combating Discrimination Against People in Treatment or Recovery
U.S. Dept of Justice. Civil Rights Division

Non-pharmacologic options for pain management October 12, 2023)
Faculty/Presenter: Ellen Dancel, PharmD, MPH
4th Wave Review - Overdose crisis described in ‘waves’ of deaths (October 5, 2023)
Presenter: George Singletary MD MPH

Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021. Addiction. 2023 Sep 13.

Series 3: September, 2023.

XBOT Study Revision (September 28, 2023)
Presenter: George Singletary MD MPH

Study: Lee JD,dt.al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018 Jan 27;391(10118):309-318.

Study PMC- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806119/

Cognitive Behavioral Therapy (CBT) for Substance Use Disorders (September 21, 2023)
Presenter: Safia Mohiuddin MD, MPH, Tulane Addiction Medicine Fellow
Long Acting Injectable (LAI) Buprenorphine: Indications and Use (September 14, 2023)
Presenter: George Singletary MD MPH
XR-BUP in Community Treatment Orders: Case Report (September 7, 2023)
Presenter: George Singletary MD MPH
-- Buprenorphine-treatment order (Antipsychotic and Opioid Agonist therapy)

Series 3: July 2023-August 2023

Racism and Addiction Treatment (August 31, 2023)
Presenter: George Singletary MD MPH
Health Care Workers and Overdose Risk (August 24, 2023)
Presenter: George Singletary MD MPH
Stimulant Hospital Admissions for OUD patients (August 17, 2023)
Presenter: George Singletary MD MPH
ASAM Criteria Application (August 8, 2023)
Presenter: George Singletary MD MPH
Buprenorphine: Administration in the Field (August 3, 2023)
Presenter: George Singletary MD MPH
Fentanyl Test Strips (July 27, 2023)
Presenter: George Singletary MD MPH
Ketamine Brief (July 20, 2023)
Presenter: George Singletary MD MPH - Sources: Rachel Barenie Pharm D JD MPH
Overdose Prevention (July 13, 2023)
Presenter: George Singletary MD MPH -- Sources: Rachel Barenie Pharm D JD MPH
McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000 Oct 4;284(13):1689-95. doi: 10.1001/jama.284.13.1689. PMID: 11015800.
Study presentation: George Singletary MD MPH
(password required for download)

Series 3: June 2023

Leyde S, Suen L, Pratt L, DeFries T. Transition from Oxycodone to Buprenorphine/Naloxone in a Hospitalized Patient with Sickle Cell Disease: A Case Report. J Gen Intern Med. 2022 Apr;37(5):1281-1285. doi: 10.1007/s11606-021-07295-2. Epub 2022 Jan 6. PMID:
Presenter: Christopher T. Patin, MD , Tulane Addiction Medicine Fellow

Article Presenter: Kathryn Germeraad, DO, Addiction Medicine (Jun 22, 2023)
Use Password: Andraka-Christou B, Totaram R, Randall-Kosich O. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses. Subst Abus. 2022;43(1):415-424. doi: 10.1080/08897077.2021.1944957. Epub 2021 Jul 2. PMID: 34214400.

Topic: ACE's, Trauma and Addiction (June 15, 2023)
Presenter - Kathryn David Germeraad, DO, Tulane Addiction Fellow Tulane - recommended article PubMed Central - Esteves KC, Jones CW, Wade M, Callerame K, Smith AK, Theall KP, Drury SS. Adverse Childhood Experiences: Implications for Offspring Telomere Length and Psychopathology. Am J Psychiatry. 2020 Jan 1;177(1):47-57. doi: 10.1176/appi.ajp.2019.18030335. Epub 2019 Sep 6. PMID: 31509004; PMCID: PMC7273739.

Research into the development of a Fentanyl Vaccine | Brainstorming application of a possible Fentanyl Vaccine (June 8, 2023) - Kathryn Germeraad, DO, Addiction Medicine Fellow, Tulane

PubMed Search
words in title: (fentanyl[Title]) AND (vaccine[Title])

Presenter: Kathryn Germeraad, DO, Addiction Medicine (June 22, 2023) Andraka-Christou B, Totaram R, Randall-Kosich O. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses. Subst Abus. 2022;43(1):415-424
Use Password to access article -- Andraka-Christou B, Totaram R, Randall-Kosich O. Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses. Subst Abus. 2022;43(1):415-424. doi: 10.1080/08897077.2021.1944957. Epub 2021 Jul 2. PMID: 34214400.

Series 3: March 2023- May 2023

Sleep Deficiency and Opioid Use Disorder: Trajectory, Mechanisms, and Interventions) - (May 25, 2023) / Stephen D. Milhollin, DO MPH , Addiction Medicine Fellow, Tulane

Langstengel J, Yaggi HK. Sleep Deficiency and Opioid Use Disorder: Trajectory, Mechanisms, and Interventions. Clin Chest Med. 2022 Jun;43(2):e1-e14. doi: 10.1016/j.ccm.2022.05.001. PMID: 35659031; PMCID: PMC10018646.
https://pubmed.ncbi.nlm.nih.gov/35659031/

Importance of motivational interviewing (May 18, 2023) Dr. Muhammad Basit, Addiction Medicine Fellow, Tulane
PubMed Search-English(2020-2023)- (((("motivational interviewing"[Title]))) OR ("Motivational Interviewing"[MAJR])) AND ("Substance-Related Disorders/therapy"[MAJR])

Case study- Research Chemical and Opioid Use Disorder (May 11, 2023)
Kathryn Davis Germeraad, DO, Tulane Addiction Medicine Fellow

Baumann MH, Tocco G, Papsun DM, Mohr AL, Fogarty MF, Krotulski AJ. U-47700 and Its Analogs: Non-Fentanyl Synthetic Opioids Impacting the Recreational Drug Market. Brain Sci. 2020 Nov 23;10(11):895. doi: 10.3390/brainsci10110895. PMID: 33238449; PMCID: PMC7700279.

Xylazine Case Report Withdrawal Managament (April 13, 2023)
Presenter: George Singletary MD MPH
Xylazine Pharmacology Brief (3-15-2023)
Presenter: George Singletary MD MPH

ARTICLE DISCUSSION (MARCH 9, 2023)- AVAILABLE FREE
Sandbrink F, Murphy JL, Johansson M, Olson JL, Edens E, Clinton-Lont J, Sall J, Spevak C; VA/DoD Guideline Development Group. The Use of Opioids in the Management of Chronic Pain: Synopsis of the 2022 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2023 Feb 14. doi: 10.7326/M22-2917. Epub ahead of print. PMID: 36780654.

Stimulant Use and Impact on Initiation of Tx for OUD (March 2, 2023)
Presenter: George Singletary MD MPH

Series 3: January-February 2023-

Harm Reduction (Fentanyl Strip Use) - (February 23, 2023) / Dr. Muhammad Basit, Addiction Medicine Fellow, Tulane

Case presentation - Fentanyl-laced cocaine - Harm reduction using fentanyl strips

PubMed Search - fentanyl test strips

Alcohol and Opioid Overdose Relationships (February 16, 2023)
Presenter: George Singletary MD MPH
Alcohol and Opioid Overdose Relationships (February 9, 2023)
Presenter: George Singletary MD MPH
Qualitative Review- Patient Centered Outcomes MOUD (January 26, 2023)
Presenter: George Singletary MD MPH
Buprenorphine and Prior Authorization (January 19, 2023)
Presenter: George Singletary MD MPH
Buprenorphine and Cravings (January 12, 2023)
Presenter: George Singletary MD MPH
Hodge Podge (January 5, 2023)
Presenter: George Singletary MD MPH

Series 3: December 2022

Methamphetamine and Psychosis (December 29,2022)
Presenter: George Singletary MD MPH
Methamphetamine and Heart Failure (December 22, 2022) -
Presenter: George Singletary, MD MPH

Study Method discussion: Manja V, Nrusimha A, Gao Y, Sheikh A, McGovern M, Heidenreich PA, Sandhu ATS, Asch S. Methamphetamine-associated heart failure: a systematic review of observational studies. Heart. 2022 Dec 1:heartjnl-2022-321610. doi: 10.1136/heartjnl-2022-321610. Epub ahead of print. PMID: 36456204.
Heart. 2022 Dec 1- PMID: 36456204.
Holiday Extravaganza! (December 15, 2022)
Faculty/Presenter: George Singletary MD MPH
Improving MOUD Access in Louisiana (December 8, 2022;Jan.14, 2022)
-- Presenter: Ford Baker, LCSW, Program Manager (SUD Clinician) -- Office of Behavioral Health, Louisiana Department of Health

Louisiana Opioid Data and Surveillance System

Opioids and Stimulants: Fatal Overdose (December 1, 2022)- Session 3, no.1
Presenter: George Singletary MD MPH

Series 2: October - November 2022.

High Dose Buprenorphine Induction in the ER (November 10, 2022)
Presenter: George Singletary MD MPH
Opioid Treatment Gap (November 3, 2022)
Presenter: George Singletary MD MPH
Mortality Rates Buprenorphine Versus Methadone (October 27, 2022)
Presenter: George Singletary MD MPH
Buprenorphine Tapering and Overdose Risk (10-20-2022)
Presenter: George Singletary MD MPH
Suggested article from discussion (password required 10-20-2022):
Danilewitz M, McLean M. High-dose buprenorphine for treatment of high potency opioid use disorder. Drug Alcohol Rev. 2020 Feb;39(2):135-137. doi: 10.1111/dar.13017. Epub 2019 Nov 25. PMID: 31769109.

Suboxone Microdosing: A case study (10/13/2022)
Presenter: Stephen D. Milhollin, MD

Ms. Harvey Goes to Washington! Advocacy in Action (10/6/2022)
Presenter: Lilly Harvey, Millie Mattered Overdose & Addiction Advocacy

Series 2: September 2022 -

Nitazenes (September 29, 2022)
Presenter: George Singletary MD MPH
Predictors of Crystal Methamphetamine Use with OAT (9-22-2022) Tulane Project ECHO Presenter: George Singletary MD MPH
Article discussed- (9-22-2022): Cui Z, et. al. Predictors of crystal methamphetamine use initiation or re-initiation among people receiving opioid agonist therapy: A prospective cohort study. Drug Alcohol Depend. 2022 Sep 10;240:109624. PMID: 36116155.
PMID: 36116155. PDF available with password:
Telehealth Addiction Treatment: Buprenorphine Availability (9-15-2022)
Faculty/Presenter: George Singletary MD MPH

Hill LG, et.al. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug Alcohol Depend. 2022 Aug 1;237:109518
Epub 2022 Jun 6. PMID: 35691255.

PDF of article above PMID: 35691255
Password Required
Telehealth Addiction Treatment (9-8-2022)
Faculty/Presenter: George Singletary MD MPH

CCHP is the National Telehealth Policy Resource Center
Recommended by Hub.

Brain Structure- adolescent brain (9-1-2022)
articles in PubMed Central (Open Access)
Faculty/Presenter: George Singletary MD MPH

Series 2: July-August 2022

Buprenorphine Perioperative Management (8-25-2022)
Faculty/Presenter: George Singletary MD MPH
Fentanyl and Methadone (August 18, 2022)
Faculty/Presenter: George Singletary, MD MPH
Marijuana and Opioids (August 11, 2022)
Post-Op Opioid Prescriptions (August 4, 2022)
Faculty/Presenter: George Singletary, MD MPH
High Dose Antagonists (July 28, 2022)
Faculty/Presenter: George Singletary,MD MPH
Pre-Addiction (July 21, 2022)
Faculty/Presenter: George Singletary,MD MPH
Social Media (July 14, 2022)
Faculty/Presenter: George Singletary MD MPH
Opioid Dose Tapering (June 30 & July 7, 2022)
Faculty/Presenter: George Singletary MD MPH

Series 2 - June 2022-

Outcomes, What are you Measuring? (June 9, 2022)
Christopher Gulde MD -- What are folks measuring? -- How are you doing it? --
Are you doing it?

References below:

Lawrinson, P., Gerber, S., Copeland, J. and Indig, D. (2003) The brief treatment outcome measure: detoxification, rehabilitation and counselling manual, Sydney: National Drug and Alcohol Research Centre.
... BTOM: Lawrinson, P., Copeland J. and Indig, D. The Brief Treatment Outcome Measure: Opioid Maintenance Pharmacotherapy
BTOM- Instrument at the end of the manual
more...less...
(NDARC Technical Report No. 156) *National Drug and Alcohol Research Centre, Sydney
National Academies of Sciences, Engineering, and Medicine. (2016). Measuring Recovery from Substance Use or Mental Disorders:
https://doi.org/10.17226/23589.
A Review of Screening, Assessment and Outcome Measures for Drug and Alcohol Settings
(2009) Written by Mark Deady (For the Network of Alcohol & other Drug Agencies (NADA) as
part of the Drug and Alcohol and Mental Health Information Management Project .
SAMHSA’s Definition of Recovery.
Measuring Recovery from Substance Use or Mental Disorders: Workshop Summary. Washington (DC): National Academies Press (US); 2016 Sep 19
Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020 Feb 5;3(2):e1920622. doi: 10.1001/jamanetworkopen.2019
WHOQOL: Measuring Quality of Life
###########

Readiness to Change (June 2, 2022) / Christopher Gulde MD
__________
references:

DiClemente CC, Schlundt D, Gemmell L. RDiClemente CC, Schlundt D, Gemmell L. Readiness and stages of change in addiction treatment. Am J Addict. 2004 Mar-Apr;13(2):103-19. doi: 10.1080/10550490490435777. PMID: 15204662.

Prochaska JO, DiClemente CC, Norcross JC. In search of how people change. Applications to addictive behaviors. Am Psychol. 1992 Sep;47(9):1102-14. doi: 10.1037//0003-066x.47.9.1102. PMID: 1329589.

The ASAM Criteria Assessment Form - Adult
Dimension 4 (Readiness to Change)
HABITS Lab
UMBC website (University of Maryland, Baltimore County)

Mee-Lee, David et al. The ASAM Criteria Treatment for Addictive, Substance-Related, and Co-Occurring Conditions. Third edition. Chevy Chase, Maryland: American Society of Addiction Medicine, 2013.
Online in R2 (Tulane single user)

Series 2 - May 2022

What the Fentanyl? / Dr. Limbaugh (May 5, 2022)
Microdosing Inductions / Dr. Limbaugh (May 12, 2022)
Macrodosing Patients / Dr. Limbaugh (May 19, 2022)
OUD Therapy in Pregnancy Dr. Limbaugh (May 26, 2022)

Series 2- April 2022

Detoxification and maintenance treatment of the geriatric chronic pain patient.
Brian Benson, MD PhD
Teenage substance use and how you can help.
Brian Benson, MD PhD
Risk assessment and interventions for teens with opioid use disorder.
Brian Benson, MD PhD

Series 2 - January - March 2022

Relapse (March 31, 2022)
Faculty Presenter: George Singletary MD MPH
References to articles discussed:

Numbers (March 24, 2022)
Faculty presenter: George Singletary MD MPH
References to articles discussed:

Stigma (March 17, 2022)
Presenter: George Singletary MD MPH

Stigma (resources)

Tobacco Use (March 10, 2022)
Faculty Presenter: George Singletary MD MPH
Addiction Consult Services (March 3,2022)
Faculty/Presenter: George Singletary MD MPH
Subcutaneous Buprenorphine (January 20, 2022)
Faculty/Presenter: George Singletary MD MPH
New Year, New Guidelines: 2021: Updated STI Testing and Treatment (1/13/2021)
Presenter: Dr. Brandon Mizroch, Brandon Mizroch, MD/MBBS
Provider Network Supervisor
Louisiana Department of Health, Office Of STDs/HIV/Hepatitis

Hepatitis C Champions - Register for Feb. 5 half day - Free CME
Recommended event

Instructions for Ordering TelePrEP Materials
Shared in session 1-13-2022
Systematic Barriers to Care (1-6-2022) - Presentation: Dr. Frederic McCall, Louisiana Department of Health
Frederic McCall MD/MBBS, MPH&TM(c)
Pronouns: He/Him/His
Provider Network Coordinator
Louisiana Department of Health
Office of Public Health - STD/HIV/Hepatitis Program
1450 Poydras St, STE 2136
New Orleans, LA 70112
Ph: (919) 920-6707

Series 2 - October-December 2021

Urine Drug Testing in Addiction Medicine (11-18-2021)
Ken Roy, MD, DLFAPA, DFASAM, Division of Addiction Medicine, Department of Psychiatry

Appropriate Use of Drug Testing in Clinical Addiction Medicine (Consensus Statement, April 5, 2017)

Kloxxado and Low Barrier (11-11-2021)
Faculty: George Singletary MD MPH
COVID and Substance Use Disorders (10-7-2021)
Faculty/Presenter: George Singletary MD MPH

Series 2 - July -- September 2021.

Treatment of Pain in the Patient with OUD (9-16-2021)
Dominick P. Trombetta, Pharm.D, BCPS, BCGP, FASCP Associate Professor, Pharmacy Practice Wilkes University, Wilkes-Barre, Pa.
Pain Management in OUD (9-16-2021)
references -

Advocacy - Millie Mattered / Lily Harvey, Advocate Presentation (8-26-2021)
Overdose Awareness Day August 29th Alexandria City Park 5-7pm.
more...less...
milliematterrs@gmail.com

Syringe Services Programs (8-19-2021)
COVID-19 Substance Use (8-12-2021)
Faculty/Presenter: George Singletary MD MPH
Kratom News (8-5-2021)
Faculty/Presenter: George Singletary MD MPH
Recovery Groups (7-29-2021)
Faculty/Presenter: George Singletary MD MPH

American Society of Addiction Medicine (ASAM) - Advocacy

ASAM Update (American Society of Addiction Medicine) - (July 8, 2021)
ASAM Advocacy / Faculty/Presenter: George Singletary MD MPH

Series 2 - June 2021.

Evolution of the Technology to Electromedicine (Auricular Acupuncture - Electrical Stimulation - Electro-Acupuncture - Percutaneous Nerve Field Stimulation) - (6-24-2021)
Bryant George, Sr, MD, FACNS, Tulane Addiction Medicine Fellow
COGNITIVE BEHAVIORAL APPROACHES - Relapse Prevention and Coping Skills Therapies - CBT
Bryant George, Sr, MD, FACNS, Tulane Addiction Medicine Fellow
RELAPSE PREVENTION STRATEGIES - Clinical Models and Intervention Strategies
Bryant George, Sr, MD, FACNS, Tulane Addiction Medicine Fellow
Recent Addiction Publications Review (6-3-2021)
Faculty/Presenter: George Singletary MD MPH

Series 2 - March-May 2021 (session slides)

Psychosocial Interventions. ln 2 parts (5-13-2021)
Faculty/Presenter: Akeem Adebayo MD MPH
Reward Systems (4-29-2021)
Faculty Presenter: George Singletary MD MPH
Sedative Hypnotic Notes (4-22-2021)
Presenter: George Singletary MD MPH
Fentanyl Notes (4-15-2021)
Faculty/Presenter: George Singletary, MD MPH
Recent Addiction Publications Review (4-8-2021)
Faculty/Presenter: George SingletaryMD MPH
Opioid Overdoses and Disproportionate Representation in Minority Communities (4-1-2021)
Faculty/Presenter: George Singletary, MD MPH
Cutting Edge Treatment of Opioid Use Disorder in the ED
Scott Weiner, MD, MPH, Associate Professor, Harvard Medical School
Director, Brigham Comprehensive Opioid Response and Education (B-CORE) Program
Trauma Response and Traits of PTSD/C-PTSD (March 11, 2021)
Presenter: Dr. Kate DuPuis, MD, MPH
Adverse Childhood Events - Trauma and Effects on Life Cycle (March 4, 2021)/
Presenter: Dr. Kate DuPuis, MD, MPH

ACE-References

Series 2 - February 2021 (Session Slides)

Switching between medications to manage Opioid Use Disorder (Feb. 25, 2021)
Presenter: Rachel Barenie PharmD JD MPH

(Feb. 11, 2021) The Louisiana Department of Health is committed to eliminating HCV
Brandon Mizroch, MD - Presentation
more...less...
brandon.mizroch@la.gov
202-321-4045

Screenings and Assessments (Feb. 4, 2021)
Faculty/Presenter: George Singletary MD MPH

--- Tools and resources for screening & assessments

Series 2 -January 2021 (Session Slides)

New Series - 2 - December 2020 (Session Slides) - PDFs

UDS Trends: Youth, Fentanyl, Stimulants and COVID /
Faculty/Presenter: George Singletary MD MPH (Dec.3, 2020)

Topic-Fentanyl

Pre-Exposure Prophylaxis for HIV PreventionPre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs
Faculty/Presenter: George Singletary MD MPH (Dec.10, 2020)

New Series - 2 - November 2020 (Session Slides) - PDFs

Why start buprenorphine in the emergency department? (Nov. 5, 2020)
Emergency Department Use of Buprenorphine / Faculty/Presenter: George Singletary MD MPH
Marijuana and Pain (Nov. 12, 2020)
Marijuana for Pain – What evidence to we have at this point? / Faculty/Presenter: George Singletary MD MPH
Stigma - (Nov. 19, 2020 )
Stigma and SUD or Words Matter / Faculty/Presenter: George Singletary MD MPH
Compassion Fatigue (Nov. 22, 2020)
Compassion Fatigue / Faculty/Presenter: George Singletary MD MPH

Introduction to Medication-Assisted Treatment (MAT) - New Series - 10-8-2020

Introduction to Medication-Assisted Treatment (MAT) -- (Update 10-8-2020) - NEW SERIES begins
General Overview continuted - Methadone & Naltrexone (Update 10-8-2020) Faculty/Presenter: George Singletary MD MPH
Introduction to Medication-Assisted Treatment (MAT) -Powerpoint Presentation 9-19-2019 - Project ECHO at Tulane University -- PDF version of the session from 9-19-2019
PDF version of the session from 9-19-2019

Recommended information: MEDICATION-ASSISTED TREATMENT (MAT)

Literature update/discussion - (Sept.23-24, 2020) / Faculty/Presenter: George Singletary MD MPH

Recent Journal Articles & ASAM Update (Sept. 23, 2020)
Faculty/Presenter: George Singletary MD MPH (Sesson #54)

Goldman-Mellor S, Olfson M, Lidon-Moyano C, Schoenbaum M. Mortality Following Nonfatal Opioid and Sedative/Hypnotic Drug Overdose. Am J Prev Med. 2020 Jul;59(1):59-67. doi: 10.1016/j.amepre.2020.02.012. Epub 2020 May 7.
Password Required until July 2021 - PMID: 32389530; PMCID: PMC7311279.

Stimulants: Sessions (Sept. 2020) / Faculty/Presenter: George Singletary MD MPH

Overview of Stimulants (Sept.2 & 3, 2020) (PDF of session slides)
Stimulants: Ilicits / Faculty/Presenter: George Singletary MD MPH
Stimulants: Literature Review (Sept. 9 & 10, 2020)
Faculty/Presenter: George Singletary MD MPH
Stimulants: Epidemiology and Contingency Management (Sept.16 and 17, 2020)
Faculty/Presenter: George Singletary MD MPH (9-16 and 9/17)
_________
References:

The Process of Recovery From Addiction (August 26 & 27, 2020) - - Dr. Ken Roy (Part 4)

The Process of Recovery From Addiction / Ken Roy, MD, FASAM - Tulane Department of Psychiatry, Division of Addiction Medicin
______
Selected resources:

Treatment of Addiction (August 19 & 20, 2020) - Dr. Ken Roy (Part 3)

Treatment of Addiction / Ken Roy, MD, FASAM - Tulane Department of Psychiatry, Division of Addiction Medicine
Session for 8/19/2020 & 8/20/2020
______
Selected resources:
Addiction a Brain Dz - Part I.
Password required - Wakefield, J. C. (2017). Addiction and the concept of disorder, Part 1: Why addiction is a medical disorder. Neuroethics, 10(1), 39–53
Addiction a Brain Dz II
Password required - Wakefield, J. C. (2017). Addiction and the concept of disorder, Part 2: Is every mental disorder a brain disorder? Neuroethics, 10(1), 55–67.

FACING ADDICTION IN AMERICA-Surgeon General’s Report on Alcohol, Drugs, and Health (2016)
HHS Publication No. (SMA) 16-4991 - Full report online

THE NEUROBIOLOGY OF SUBSTANCE USE, MISUSE, AND ADDICTION Chapter 2
PDF available

Some Opioid Agonists You May Not Know, But Your Patients Might. (July 29 & 30, 2020)

Some Opioid Agonists You May Not Know, But Your Patients Might./ George Singletary, MD MPH
Mitragynine (Kratom) -- Tianeptine -- Isotonitazene -- Brorphine

FDA and Kratom
The U.S. Food and Drug Administration is warning consumers not to use Mitragyna speciosa, commonly known as kratom ... [09/11/2019]
PubMed Search
(((Mitragynine OR Kratom) OR (Tianeptine)) OR (Isotonitazene)) OR (Brorphine)

Urine Drug Testing in Addiction Medicine (August 5 and 6 | Aug 12 and 13) / Dr. Ken Roy (Parts 1-2)

Urine Drug Testing in Addiction Medicine
Presenter: Ken Roy, MD, DLFAPA, DFASAM Division of Addiction Medicine

Barthwell - PDF- password required

Buprenorphine Micro Induction (July 22 and 23, 2020)

Buprenorphine Micro Induction / George Singletary MD MPH

An Update on Home induction (July 15 & 16, 2020) / George Singletary

Buprenorphine Home Induction / Faculty/Presenter: George Singletary MD MPH

ASAM.org (Patient Information) IT MATTERs - a patient's guide to starting Buprerenorphine at home.
ASAM.org
more...less...
Adapted from NYU School of Medicine Division of General Internal Medicine and PCSS-MAT. Created in partnership with the High
Plains Research Network Community Advisory Council for IT MATTTRs. For permission to use outside of IT MATTTRs, please contact
ITMATTTRsColorado@ucdenver.edu.
Buprenorphine - Beginning Treatment
NYU School of Medicine Division of General Internal Medicine / J. Lee
Recommended references: BUPRENORPHINE INDUCTION
PubMed Search - Buprenorphine Home Induction
Search: ("Buprenorphine/administration and dosage"[MeSH]) AND ((home induction) OR (( "Addiction Medicine/methods"[Mesh] OR "Addiction Medicine/standards"[Mesh] OR "Addiction Medicine/trends"[Mesh] )))

Withdrawal Symptom Management (July 7 & 8, 2020) / George Singletary

Withdrawal Symptom Management (July 7 & 8, 2020) / George Singletary

Scales / Resources
COWS - SOWS - OWS - SOWSGossop

An Update on Fentanyl (July 1 & 2, 2020) / George Singletary

An Update on Fentanyl (July 1 & 2, 2020)
Presenter: George Singletary MD MPH

Topic-Fentanyl

Substance Use Disorders in Pregnancy (Series of Sessions, June 2020) / Julianna Finelli, MD

Perinatal substance use - (6/3/2020 or 6/4/2020)
Julianna Finelli, MD, Assistant Professor of Psychiatry, Tulane University School of MedicineLead Psychiatrist, Louisiana Mental Health Perinatal Partnership (LAMHPP)
Substance Use Disorders in Pregnancy (June 9 & 10, 2020)
Julianna Finelli, MD
Early Identification of Perinatal Mental Health Problems / Julianna Finelli, MD
Screening
Treating Perinatal Mental Health Problems / Julianna Finelli, MD
Breastfeeding and Parenting Considerations / Julianna Finelli, MD

Louisiana Mental Health Perinatal Partnership (LAMHPP)
Program Brochure Available , www.lamhpp.org

TANF Residential Programs (PDF)
Accepting new patients (with COVID-19 precautions in place)- 6/4/2020

SAMHSA. Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants. HHS Publication No. (SMA) 18-5054. Substance Abuse and Mental Health Services Administration, 2018.
PDF publication
___________________
Nicotine / Pregnancy
ACOG Clinical. Opioid Use and Opioid Use Disorder in Pregnancy - Committee Opinion - CO-Number 711(August 2017)
711 (Replaces Committee Opinion Number 524, May 2012) - Committee on Obstetric Practice & American Society of Addiction Medicine

Claire R, et.al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2020 Mar 4;3(3):CD010078.
PMID: 32129504; PMCID: PMC7059898.

Hickson C, et.al. Comparison of nicotine exposure during pregnancy when smoking and abstinent with nicotine replacement therapy: systematic review and meta-analysis. Addiction. 2019 Mar;114(3):406-424.
PMID: 30315598; PMCID: PMC6590470.

Managing Pain in Patients with OUD (Series of sessions) / Rachel Barenie, PharmD, JD, MPH

Part 1. Non-pharmacologic options (May 6 & 7, 2020)
Presenter: Rachel Barenie, PharmD, JD, MPH
Part 2: Non-opioid pharmacologic options (May 13 & 14, 2020)
Managing Pain in Patients with OUD Part 2 / Presenter: Rachel Barenie, PharmD, JD, MPH
Part 3: Opioid pharmacologic options (May 20 and 21, 2020)
Part 4: Considerations for surgery (May 27 & 28, 2020)
____________
Selected resources:

Managing chronic non-cancer pain: Evidence-based strategies to reduce opioid use / Principal Consultants: Brian Bateman M.D., M.Sc. and Katsiaryna Bykov, PharmD, Sc.D. (provided by Alosa Health)
Link to online document (PDF)
OPIOIDS IN ACUTE PAIN / Alosa Health Acute Pain Module
OPIOIDS IN CHRONIC PAIN - Alosa Health Chronic Pain Module
ASAM Clinical Guidelines
2020 National Practice Guideline - Access the full the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder - 2020 Focused Update.
Webster et al. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. Pain Medicine. 2020;0(0):1-10.
PubMed Central (free access)
Perioperative Buprenorphine Continuous Maintenance and Administration Simultaneous With Full Opioid Agonist: Patient Priority at the Interface Between Medical Disciplines. J Clin Psychiatry. 2020 Jan 7;81(1):19
PMID: 31917908. (Free PDF)
Kornfeld H, Manfredi L. Effectiveness of full agonist opioids in patients stabilized on buprenorphine undergoing major surgery: a case series. Am J Ther. 2010;17(5):523‐528.
PMID: 31917908.. (Free PDF)

Rudolf G. Buprenorphine in the Treatment of Chronic Pain. Psy Med Rehabil Clin N Am. 2020;May;31(2):195-204.
PMID: 32279723 (Password required for PDF)
"Pain and Addiction”, (chapter 9) p.123-35.
"Pain and Addiction”, (chapter 9) by Ilene Robeck and Stephen A. Mudra. In Pangarkar, Sanjong. Pain Care Essentials and Innovations (2021) , Chapter 9, p. 123-135 (requires password)

HCV - Hepatitis C Virus (April 2020) / Dr.Dr. Brandon Mizroch

HCV Basics for Project ECHO
Brandon Mizroch MD/MBBS, Provider Network Supervisor, Louisiana Department of Health. Office of Public Health, STD/HIV/Hepatitis Program
HCV Streamlined Test and Treat Algorithm / Brandon Mizroch, MD/MBBS, Louisiana Department of Health
April 15 & 16, 2020
[Generic Epclusa (sofosbuvir/velpatasvir) Direct Acting Antiviral (DAA)]
_______________
HCV handouts / information
ALGORITHMS: SCREENING FOR ADULT PATIENTS* Therapy for HCV
Reference Card (PDF)
Hepatitis Vaccinations
HCV ICD10 codes
Interpretation of Hepatitis Screening Test Results / Louisiana Department of Health
Six Interpretations of Hepatitis Screenings

Taking control of Hep C./ Hep C Free LA
Louisiana Department of Health - HepC Statistics
Provider Packet for Hep C Prevention Project
Medical facility or provider in Louisiana that treats Hepatitis C.
Hepatitic C Online
Clinical Calculators
Monitoring of Liver Function Tests in Patients Receiving Naltrexone or Extended-Release Naltrexone / PCSS Guidance
PDF document
more...less...
ref provided by Barenie, Rachel E.

Legal Series (March 2020) / Presenter: Daniel C. McClughen, JD, Counsel to Center for U.S. Policy; Associate Attorney, DCBA Law & Policy LLP

Prescribersafety.org
"Understand and adhere to the laws and regulations governing the prescribing of controlled medications, including office-based opioid treatment."

ETHICAL AND LEGAL ISSUES (cited materials)

Naloxone for Patients with Opioid Use Disorder (Feb.26, 2020)

Naloxone for Patients with Opioid Use Disorder / Presenter: Rachel Barenie PharmD JD MPH (Feb.26, 2020)
PDF of presentation - (no.25, Feb. 26, 2020)

See literature reviewing supporting evidence for Naloxone use and availability.
Links provided to PubMed or PubMed Central - Plus links to guidelines and training videos from presentation.

Selecting a medication to manage Opioid Use Disorder (Feb. 19 & 20, 2020)

Selecting a medication to manage Opioid Use Disorder / Presenter: Rachel Barenie PharmD JD MPH - (no.24, Feb. 19 & 20, 2020)
PDF of presentation - (no.24, Feb. 19 & 20, 2020)

Evidence supporting medication use to manage Opioid Use Disorder (Feb.12&13, 2020)

Evidence supporting medication use to manage Opioid Use Disorder / Presenter: Rachel Barenie PharmD JD MP
PDF of presentation - (no.23, Feb.12&13, 2020)

See literature reviewing supporting evidence. Links provided to PubMed or PubMed Central:
Reference links from presentation

Medications for Opioid Use Disorder (February 5 and 6, 2020)

Medications for Opioid Use Disorder / Presenter: Rachel Barenie PharmD JD MPH
PDF of Session presentation (no.22- Feb. 5 & 6, 2020)

Buprenorphine Induction (January 29 & 30, 2020)

Buprenorphine Induction /Faculty/Presenter: George Singletary, MD MPH
PDF version of slides (no.21,Jan. 2020) - references link to PubMed Central or article as available.

Recommended references: BUPRENORPHINE INDUCTION

Sensible Tapering (Jan 22 & 23, 2020)

Sensible Tapering: Reasoning and Methods (1-22 & 23 -2020) / Faculty/Presenter: George Singletary MD MPH
PDF version of session (no.20, Jan. 2020) slides.

Recommended references: TAPERING AND DISCONTINUATION

Infectious Diseases & OUD (Jan 15 &16, 2020)

Infectious Disease and PWID / Faculty/Presenter: George Singletary MD (Jan 15 &16, 2020)
PDF version of session presentation (no.19)
HCV Champions Project - ECHO Flyer
Project ECHO presents: Louisiana HCV Elimination Program
HCV Provider Training / Gia L. Tyson, MD, MPH & Frederic McCall MD/MBBS, MPH&TM(c)

Supplemental information: INFECTIOUS DISEASES -

Anatomy and Neurochemistry of Addiction (Jan. 8 & 9, 2020)

Anatomy and Neurochemistry of Addiction / Faculty/Presenter: George Singletary MD MPH
PDF version of session presentation no. 18 (1-8/9-2020)

Suggested references: NEUROCHEMISTRY / BRAIN ANATOMY

Criminal Justice and OUD (01-02-2020)

Criminal Justice and OUD / Faculty/Presenter: George Singletary MD MPH
PDF version of session, no.17, (Jan. 2, 2020)

Recommended References: CRIMINAL JUSTICE:

Urine Drug Testing (12/26/2019)

Lab Testing in the Assessment of Substance Use Disorders (12-26-2019) #16
Faculty/Presenter: Dr. George Singletary, MD, MPHTulane

PubMed Search - ("Substance-Related Disorders/urine"[MAJR]) AND "Drug Monitoring/methods"[MAJR]
PubMed

PDF - Clin J Pain. 2002 Jul-Aug;18(4 Suppl):S76-82.
Password Required

Co-Occurring Disorders and Mortality (12-12-2019)

Co-Occurring Disorders and Mortality (12-12-2019) #14
Faculty/Presenter: Dr. George Singletary, MD, MPH

See suggested resources:

Ethical and Legal Issues in Substance Abuse Treatment (12-19-2019)

Ethical and Legal Issues in Substance Use Treatment (12-19-2019) #15
Faculty/Presenter: Dr. George Singletary, MD, MPH

Bioethics, Public Health and the Social Sciences for the Medical Professions by Amy E. Caruso Brown (Editor); Travis R. Hobart (Editor); Cynthia B. Morrow (Editor)
ISBN: 9783030035433
Publication Date: 2019-08-17
SpringerLink (Medicine 2019)

“I’m in Pain!” / Theresa Baxter
Chapter PDF, password required.

PubMed Search
more...less...
(("Opioid-Related Disorders"[Majr]) AND ("Legislation as Topic"[Mesh] OR "Legislation" [Publication Type] OR "legislation and jurisprudence" [Subheading] OR "Legal Case" [Publication Type])) AND ("Ethics"[Mesh] OR "ethics" [Subheading] OR "Ethics, Research"[Mesh] OR "Ethics Committees, Clinical"[Mesh] OR "Principle-Based Ethics"[Mesh] OR "Ethics, Clinical"[Mesh] OR "Bioethics"[Mesh])

Risk Reduction and Safe Use of Opioids (Dec.5, 2019)

Risk Management and Best Practice for Safe Opioid Prescribing (PDF) / Presenter: George Singletary MD MPH (12-5-2019)
PDF version (12-5-2019)

PubMed Search on topic:
(("Analgesics, Opioid/adverse effects"[MAJR]) AND "Opioid-Related Disorders/therapy"[MAJR]) AND ("Pain, Postoperative/prevention and control"[MeSH Terms])

Management Opioid Withdrawal and Preventing Overdose ( Part 2)- (11-21-2019)

Preventing Opioid Overdose with Education and Naloxone Rescue Kits (11-21-2019) - Part 2
Management Opioid Withdrawal and Preventing Overdose / Faculty/Presenter: Dr. George Singletary, MD, MPH

Adolescent Substance Use (11-14-2019)

Adolescent Substance Use / Presenter: Dr. George Singletary, MD, MPH Tulane School of Medicine, Psychiatry Chair: Dr. John Thompson, MD Program Facilitator: Claudia Achoja, MSN, FNP-C Program Administrator: Kevin Massey, MS
PDF of Session from 11-14-19

Supplemental information: ADOLESECENT SUBSTANCE USE

Pregnancy and OUD (11-7-1219)

Opioid Use Disorder Pregnancy / Presenter: George Singletary MD MPH
PDF version of powerpoint slides.

Trauma-Informed Care & OUD (10-31-2019)

Trauma-Informed Care & OUD
PDF version (Session #8 (10-31-2019): Presenter: Claudia Achoja, MSN, FNP-C

Adverse childhood experiences (ACEs) and Opioid Addiction (10/24/2019))

ACEs and Addiction: How Adverse Childhood Experiences Can Help us Understand People with Substance Use Disorders
PDF verson: #7. Session from 10/24/2019

Recommended References: ADVERSE CHILDHOOD EXPERIENCES (ACEs)

STIGMA AND OPIOID USE DISORDER (10-10-2019)

Stigma and Opioid Use Disorder (10-10-2019) / Dr. George Singletary, MD, MPH
PDF Version

MOTIVATIONAL INTERVIEWING (10-3-2019)

Motivational Interviewing for Primary Care Physicians (PDF) / Presenter: George Singletary MD MPH (10-3-2019)
PDF version (10-3-2019)

Suggested Resources: MOTIVATIONAL INTERVIEWING

Operating a MAT Clinic: The nuts & bolts ( 9/26/2019) - MAT Clinic Process and Workflow

MAT Clinic Process and Workflow 9-26-2019.pdf
PDF Version: Operating a MAT (medication-assisted treatment) Clinic: The nuts & bolts / Presenter/Faculty: Dr. George Singletary, MD, MPH 9/26/2019

Tulane University LaSOR Project ECHO (Extension For Community Healthcare Outcomes)